PMID- 23465037
OWN - NLM
STAT- MEDLINE
DCOM- 20141208
LR  - 20151119
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 28
IP  - 5
DP  - 2014 May
TI  - Disease characteristics in patients with and without psoriatic arthritis treated 
      with etanercept.
PG  - 581-9
LID - 10.1111/jdv.12138 [doi]
AB  - BACKGROUND: Patients with psoriasis (PsO) and psoriatic arthritis (PsA) have 
      functional disability, pain and emotional problems, and experience lower quality 
      of life (QoL) than patients with PsO alone. OBJECTIVES: Examine effectiveness of 
      etanercept (ETN) in patients with PsO alone, and with PsA, and determine whether 
      PsA patients on ETN experience rapid QoL improvement. METHODS: Data from three 
      phase III trials using ETN in adults with moderate-to-severe PsO were pooled. 
      Patients with (n = 523) and without (n = 1330) PsA received ETN 25 mg once weekly 
      to 50 mg twice weekly or placebo for 12-24 weeks. Assessments included Psoriasis 
      Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), EuroQoL-5D 
      (EQ-5D), Study 36-item Short Form Health Survey (SF-36) and Hamilton Depression 
      Rating Scale (HAM-D). RESULTS: Baseline PASI, EQ-5D and SF-36 physical component 
      summary scores were worse for PsA patients. With ETN, PASI for PsA and non-PsA 
      groups improved as early as week 2. Scores for both groups converged by week 12. 
      EQ-5D and SF-36 physical component improved faster in PsA patients, with EQ-5D 
      scores converged by week 2. For total DLQI and most components, both groups had 
      similar baseline scores and improved over 24 weeks on ETN. While the PsA group 
      had more depressed patients at baseline, after 24 weeks on ETN it showed a 
      greater reduction in the number of depressed patients than the non-PsA group. 
      CONCLUSIONS: In patients with PsO involving >/=10% of body surface area, skin 
      disease and QoL are worse in PsA patients. With ETN, QoL improved rapidly in PsA 
      patients.
CI  - (c) 2013 The Authors Journal of the European Academy of Dermatology and Venereology 
      (c) 2013 European Academy of Dermatology and Venereology.
FAU - Papp, K
AU  - Papp K
AD  - Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.
FAU - Poulin, Y
AU  - Poulin Y
FAU - Vieira, A
AU  - Vieira A
FAU - Shelton, J
AU  - Shelton J
FAU - Poulin-Costello, M
AU  - Poulin-Costello M
LA  - eng
SI  - ClinicalTrials.gov/NCT00111449
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Arthritis, Psoriatic/*drug therapy/physiopathology
MH  - Case-Control Studies
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Surveys and Questionnaires
EDAT- 2013/03/08 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/03/08 06:00
PHST- 2012/11/22 00:00 [received]
PHST- 2013/02/15 00:00 [accepted]
PHST- 2013/03/08 06:00 [entrez]
PHST- 2013/03/08 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/jdv.12138 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2014 May;28(5):581-9. doi: 10.1111/jdv.12138. Epub 
      2013 Mar 7.